These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23445367)

  • 41. Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14.
    Gutiérrez A; Bento L; Bautista-Gili AM; Garcia F; Martinez-Serra J; Sanchez B; Martorell C; Gines J; Garcia L; Gimeno E; Ferraro M; Del Campo R; Bargay J; Perez A; Vercher J; Scaff M; Pacheco A; Ballester C; Garcia F; Ramos R; Salar A; Besalduch J
    PLoS One; 2015; 10(4):e0123978. PubMed ID: 25909361
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
    J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
    Kumar A; Lunning MA; Zhang Z; Migliacci JC; Moskowitz CH; Zelenetz AD
    Br J Haematol; 2015 Dec; 171(5):776-83. PubMed ID: 26456939
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Yoo C; Lee DH; Kim JE; Jo J; Yoon DH; Sohn BS; Kim SW; Lee JS; Suh C
    Ann Hematol; 2011 Jul; 90(7):797-802. PubMed ID: 21181163
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.
    Dakhil S; Hermann R; Schreeder MT; Gregory SA; Monte M; Windsor KS; Hurst D; Chai A; Brewster M; Richards P
    Leuk Lymphoma; 2014 Oct; 55(10):2335-40. PubMed ID: 24471908
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.
    Derenzini E; Stefoni V; Pellegrini C; Fina MP; Broccoli A; Venturini F; Gandolfi L; Pileri SA; Martelli M; Petti MC; Perrotti A; De Renzo A; Zaja F; Baccarani M; Zinzani PL
    Leuk Lymphoma; 2009 Nov; 50(11):1824-9. PubMed ID: 19814687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
    J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma.
    Nobili S; Napoli C; Puccini B; Landini I; Perrone G; Brugia M; Benelli G; Doria M; Martelli M; Finolezzi E; Di Rocco A; Del Fava E; Rigacci L; Di Lollo S; Bosi A; Mini E
    Leuk Lymphoma; 2014 Sep; 55(9):2071-8. PubMed ID: 24289107
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma.
    Marcheselli L; Marcheselli R; Bari A; Liardo EV; Morabito F; Baldini L; Brugiatelli M; Merli F; Di Renzo N; Sacchi S
    Leuk Lymphoma; 2011 Oct; 52(10):1867-72. PubMed ID: 21663499
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival.
    Borel C; Lamy S; Compaci G; Récher C; Jeanneau P; Nogaro JC; Bauvin E; Despas F; Delpierre C; Laurent G
    BMC Cancer; 2015 Apr; 15():288. PubMed ID: 25884669
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
    George A; Tam CS; Seymour JF
    Leuk Lymphoma; 2013 Dec; 54(12):2575-6. PubMed ID: 23597141
    [No Abstract]   [Full Text] [Related]  

  • 54. [Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: clinicopathologic characterization of 16 cases showing different patterns].
    Wang L; Wang W; Li X; Guo Y; Zhu X
    Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):307-12. PubMed ID: 25030862
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Consolidation anti-CD22 fractionated radioimmunotherapy with
    Kraeber-Bodere F; Pallardy A; Maisonneuve H; Campion L; Moreau A; Soubeyran I; Le Gouill S; Tournilhac O; Daguindau E; Jardel H; Morineau N; Bouabdallah K; Gyan E; Moles MP; Gressin R; Berthou C; Sadot S; Moreau P; Deau B; Bodet-Milin C; Cazeau AL; Garin E; Salaun PY; Vuillez JP; Gouilleux-Gruart V; Barbet J; Wegener WA; Goldenberg DM; Lamy T; Soubeyran P
    Lancet Haematol; 2017 Jan; 4(1):e35-e45. PubMed ID: 27964867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.
    Mian M; Augustin F; Kocher F; Gunsilius E; Willenbacher W; Zabernigg A; Zangerl G; Oexle H; Schreieck S; Schnallinger M; Fiegl M
    Anticancer Res; 2014 May; 34(5):2559-64. PubMed ID: 24778077
    [TBL] [Abstract][Full Text] [Related]  

  • 57. R-CHOP versus R-COMP: are they really equally effective?
    Mian M; Wasle I; Gamerith G; Mondello P; Melchardt T; Jäger T; Linkesch W; Fiegl M
    Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):648-52. PubMed ID: 24929649
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of diffuse large B-cell lymphoma (DLBCL).
    Kubuschok B; Held G; Pfreundschuh M
    Cancer Treat Res; 2015; 165():271-88. PubMed ID: 25655614
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical characteristics and treatment strategies for early-stage primary gastric diffuse large B-cell lymphoma].
    Qin Y; Liu P; Yang JL; Jin J; He XH; Wang WH; Fang H; Zhou SY; Zhou LQ; Song YW; Shi YK
    Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(24):1945-1950. PubMed ID: 29996288
    [No Abstract]   [Full Text] [Related]  

  • 60. The unexpected evolution of a case of diffuse large B-cell non-Hodgkin lymphoma.
    Găman A; Bold A; Găman G
    Rom J Morphol Embryol; 2011; 52(2):719-22. PubMed ID: 21655667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.